Linklaters advises on rights issue by DocMorris AG

Linklaters advised UBS, BofA Securities, Zürcher Kantonalbank and ING Bank in connection with the rights issue by DocMorris AG with gross proceeds of around CHF 200 million.

The company's shareholders approved the rights issue at the Annual General Meeting on May 8, 2025. DocMorris plans to use the proceeds to finance the planned medium-term growth in the prescription medicines (Rx) business, including incrementally targeted Rx marketing spend, as well as a potential repayment of a CHF 95 million convertible bond in September 2026.

The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries.

The Linklaters team was led by Dr Marco Georg Carbonare (Partner, Corporate/M&A) and Alexander Auster (U.S. Associate, both Frankfurt). Other team members included Dr Jana Hager (Partner, Public & Administrative Law, Berlin), Omer Harel (Counsel, Tax, London), Kevin Roy (U.S. Counsel, Berlin), John Hunt (U.S. Senior Associate, Frankfurt), Justin Faulhaber (U.S. Associate, Frankfurt), Florian Kopp (Associate, Public & Administrative Law Berlin), Young Jin Kim (U.S. Associate, Tax, New York) and Wladislaw Kirch (Transaction Lawyer, Corporate, Frankfurt).